Yi Yang - research works

A comprehensive search across multiple databases identified randomized controlled trials comparing FCM with other iron formulations.

The overall incidence of drug-related adverse events was comparable between groups (risk ratio = 0.82, 95% CI: 0.51-1.34); however, FCM was associated with a substantially increased risk of hypophosphatemia (risk ratio = 21.00, 95% CI: 8.90-49.56).

There were no significant differences in baseline characteristics (age, gender, BMI, surgical parameters, scoliosis type, preoperative/postoperative Cobb angles) between the two groups (all p > 0.05).

Preoperatively, SRS-22 and SF-36 scores showed no inter-group differences (all p > 0.05).

Both groups showed significant improvements in physical function-related dimensions postoperatively.

The Non-Negative Emotion Group also exhibited significant improvements in SRS-22 self-image/pain and SF-36 bodily pain (all p < 0.05), while the Negative Emotion Group showed no significant improvements in these dimensions.

The overall pump-twin survival rate was 65.8% (77/117).

Three variables (URL and URL/CRL ratio in the first trimester and TWR in the second trimester) were identified to be independent risk factors influencing pump-twin survival in both the primary and external-validation cohorts.

The TWR exhibited good calibration, but URL and the URL/CRL ratio exhibited poor calibration.

However, the optimal cut-offs of URL and the URL/CRL ratio showed no statistical difference in the external-validation cohort.

Nevertheless, the multi-omics framework yielded superior balance across accuracy and F1 score.

SHAP analysis identified key determinants of treatment response, including CLEC2A, MYH4, and methylation of SYT12_1, with functional enrichment implicating immune regulation, metabolic pathways, and drug resistance signaling.

Experimental validation confirmed six hub genes (CASP8, AQP8, CAV1, FN1, CREB1, KDR), exhibiting expression patterns associated with drug resistance, immune regulation, and prognosis.

31.6% [12/38]; OR 0.29, 95%CI 0.10-0.89; p = 0.03).

Heart rate and mean arterial pressure were lower in Group A at specific intraoperative time points ( p < 0.05).

Extubation time, Aldrete scores, and postoperative pain scores were comparable between groups ( p > 0.05).

No opioid-related adverse events were observed.

To overcome these limitations, an eye positioning and monitoring system (EPMS) was developed.

A gaze range analysis algorithm and an occlusion zone analytical algorithm for the beam path and cameras were proposed.

The EPMS mechanical guidance range reached 360° azimuth and 60.1° maximum polar, while identifying specific exclusion zones.

Stability tests demonstrated cumulative workflow errors were always ≤ 0.22 mm and 0.01° for the guidance module, and ≤ 0.20 mm and 0.1° for the monitoring module.

The prevalence of multimorbidity was 38.95%.

Higher C-index and BRI quartiles were significantly associated with increased multimorbidity risk.

A dose-response relationship was observed ( p < 0.001).

BRI showed statistically significantly higher discriminative ability relative to traditional anthropometric indices, though its overall discriminative performance was modest (AUC = 0.678).

The 18-month SCAR-Q score was available for 155 patients (8 missing, 4 per group).

One patient in the C-O-BCS group developed bone metastasis at 5 months, and another developed axillary lymph node recurrence at 17 months.

No local recurrence or death occurred in either group.